Previous 10 | Next 10 |
Bluebird bio (NASDAQ: BLUE ) Q4 result s ($M): 18.4 (+357.1%). More news on: bluebird bio, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
bluebird bio (NASDAQ: BLUE ): Q4 GAAP EPS of -$2.72 beats by $0.12 . Revenue of $19.24M (+361.4% Y/Y) beats by $10.67M . Press Release More news on: bluebird bio, Inc., Earnings news and commentary, Healthcare stocks news,
- Strong 2018 marked by the company’s first European Marketing Authorization Application for LentiGlobin in transfusion-dependent β-thalassemia (TDT) – - Data across LentiGlobin studies in TDT and sickle cell disease (SCD) and bb21217 in multiple myeloma presented ...
In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...
NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Tyson Foods, Inc. (NYSE:TSN), ElectraMeccanica Vehicles Corp. (NASDAQ:...
Bluebird bio (NASDAQ: BLUE ) appoints Chip Baird as Chief Financial Officer (CFO), effective immediately. Mr. Baird joins bluebird from Amicus Therapeutics, where he was the CFO for the past seven years. More news on: bluebird bio, Inc., Healthcare stocks news, Read more .....
CFO with proven track record will help lead transition to commercial company Jeff Walsh to assume role of chief strategy officer Jason Cole to assume role of chief operating and legal officer bluebird bio, Inc . (Nasdaq:BLUE) announced Chip Baird will join the company effec...
Recent Company Background: bluebird bio ( BLUE ) is one of the larger ($7.4B market cap) pure biotechs focused on the cell/gene therapy and CAR-T space. They have recently been making the rounds in the news regarding their exciting developments . Although they are a diverse biotech, looking...
Quick Take TCR2 Therapeutics ( TCRR ) intends to raise gross proceeds of $75 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing therapies that harness the patient's immune system to fight cancer irrespective of human leukocyte antigens [HLA] sub...
NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged at 2.25% to 2.50%. The Dow Jones Industrial Average went higher by 1.77 percent to ...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...